



Universiteit  
Leiden  
The Netherlands

## **Vulvar cancer : pathogenesis, molecular genetics and treatment**

Nooij, L.S.

### **Citation**

Nooij, L. S. (2018, June 28). *Vulvar cancer : pathogenesis, molecular genetics and treatment*. Retrieved from <https://hdl.handle.net/1887/62866>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/62866>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/62866> holds various files of this Leiden University dissertation

**Author:** Nooij, Linda

**Title:** Vulvar cancer : pathogenesis, molecular genetics and treatment

**Date:** 2018-06-28

## CHAPTER 5

### **Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature**

Marjolijn D. Trietsch\*

Linda S. Nooij\*

Katja N. Gaarenstroom

Mariette I.E. van Poelgeest

\* Both authors contributed equally

*Gynecologic Oncology 2015;136:143-157*

## Abstract

Vulvar cancer is a relatively rare gynecologic malignancy with an annual incidence in developed countries of approximately 2 per 100,000 women. Vulvar squamous cell carcinoma (VSCC) has two etiological pathways: a high risk human papillomavirus (HPV)-dependent route, which has usual vulvar intraepithelial neoplasia (uVIN) as a precursor lesion, and an HPV-independent route, which is associated with differentiated VIN (dVIN), lichen sclerosus, and genetic alterations, such as *TP53* mutations. Research on the molecular etiology of vulvar cancer has increased in past years, not only regarding genetic alterations, but also epigenetic changes. In genetic alterations, a mutation irreversibly changes the nucleotide sequence of the DNA, or the number of copies of chromosomes per cell is altered. In epigenetics, the nucleotide sequence remains the same but genes can be 'switched' on or off by, for example, DNA methylation or histone modification. We searched the current literature on genetic and epigenetic alterations in VSCC and its precursor lesions. Many studies have reported a higher incidence of somatic mutations in HPV-negative tumors compared to HPV-positive tumors, with *TP53* mutations being the most frequent. These somatic mutations seem to occur more often with increasing grades of dysplasia. Allelic imbalances or loss of heterozygosity are more frequently found in higher stages of dysplasia and in invasive carcinomas, but it is not exclusive to HPV-negative tumors. A limited number of studies are available on epigenetic changes in vulvar lesions, with hypermethylation of *CDKN2A* being the most frequently investigated change. For most genes, hypermethylation occurs more frequently in VSCC than in precursor lesions. As most studies have focused on HPV infection and *TP53* mutations, we suggest that more research should be performed using whole genome or next generation sequencing to determine the true landscape of genetic and epigenetic alterations in VSCC.

## Introduction

Vulvar cancer is a rare malignant disease accounting for less than 5% of gynecological malignancies (1-3). The majority of these tumors are vulvar squamous cell carcinoma (VSCC). The annual incidence of VSCC in developed countries is two to three per 100,000 women and increases with age, with a peak incidence between 60 and 70 years of age (1, 4, 5).

The pathogenesis of VSCC can be subdivided into two different pathways: human papillomavirus (HPV)-dependent and HPV-independent (1-7). The HPV-dependent pathway accounts for 20-40% of VSCCs and has usual vulvar intraepithelial neoplasia (uVIN) as a precursor lesion (3, 4, 8). This pathway is more common in younger women and is associated with smoking, a higher number of sexual partners, and a compromised immune status (1, 3, 9). The incidence of VIN, especially the usual type, has increased in the last couple of years, even doubling in some countries (1, 4-6). The risk of the progression of a uVIN lesion towards VSCC seems low, occurring in 9-16% of patients who do not receive treatment and in approximately 3% of patients who have been treated (1, 6). However, some studies have reported a higher risk of progression (10, 11). The non-HPV pathway is associated with mutations in *TP53* and mainly occurs in older women (1-3, 6, 7). This pathway is associated with lichen sclerosus (LS), a chronic dermatosis associated with autoimmune diseases. Approximately 3-5% of women with LS progress towards VSCC (9, 12). Differentiated VIN (dVIN) is considered to be a precursor lesion of HPV-independent VSCC, with a higher malignant potential than uVIN (1, 6). dVIN can be difficult to diagnose for both clinicians and pathologists because of its subtle clinical and histological appearance (13). HPV-independent VSCC is associated with a worse prognosis than HPV-associated VSCC (3, 9). However, its carcinogenesis has not been fully clarified.

When diagnosed at an early stage, VSCC has a good prognosis, especially for patients without inguinofemoral lymph node metastasis at first presentation (14). Unfortunately, approximately one-third (15) of patients suffer from recurrent disease. In the latter group of patients, therapeutic options are limited due to severe morbidity associated with repeated treatment of local recurrences. Recurrent disease in inguinal lymph nodes has a very poor prognosis and is almost always fatal (16, 17). Information on genetic and epigenetic changes that play a role in the carcinogenesis of vulvar cancer may provide valuable insight into its etiology. Studies of many different types of cancer have shown that genetic and epigenetic alteration status can help predict prognosis and guide targeted therapy (18-23). For example, vemurafenib, a BRAF inhibitor, has shown clinical efficacy as targeted therapy for melanomas that harbor mutations in *BRAF* (24). In HPV-negative VSCC, mutations are often found in


the tumor suppressor gene *TP53* (1, 8, 9, 25, 26). *TP53* mutations are thought to be an early event in the development of VSCC because they are also found in dVIN and LS lesions (1, 6-8, 26). Other mutations have been described in VSCC and its precursor lesions, including mutations in the tumor suppressor genes *PTEN* and *CDKN2A* (27, 28). Other types of genetic alterations are allelic imbalances or copy number alterations, in which the number of copies of chromosomes per cell is altered. In addition to genetic mutations, epigenetic changes may also play a role in the development of VSCC. Epigenetic changes are defined as heritable changes in gene expression without changes in the DNA sequence. The best known epigenetic change is hypermethylation of CpG islands in the promoter regions of tumor suppressor genes, causing inactivation of the gene (19, 23, 29-32). In vulvar cancer, hypermethylation of the promoters of *RASSF2A*, *MGMT*, and *TSP1* has been described (30). Here, we review the current literature and summarize the current understanding of the role of genetic and epigenetic changes in VSCC and its precursor lesions.

## **Materials and methods**

Relevant studies on genetic alterations (somatic mutations, allelic imbalances, loss of heterozygosity, copy number changes, and microsatellite instability) and epigenetic changes (hypomethylation and hypermethylation, microsatellite instability, and chromatin, histone, and posttranscriptional modifications) were identified from an extensive search on PubMed, Embase, Web of Science, Cochrane, and ScienceDirect. After consulting a medical librarian, a combination of Medical Subject Headings (MeSH) and free text words were formulated. Our search included the terms vulvar neoplasm, vulvar carcinoma, vulvar intraepithelial neoplasia, lichen sclerosus et atrophicus, mutation, microsatellite instability, genetic, epigenetic, hypermethylation, chromatin, histone, and posttranscriptional modifications. Research published until 31 July 2014 that studied somatic mutations and epigenetic changes in VSCC, VIN, and/or LS were included in this review. Exclusion criteria were languages other than English, Dutch, German, French, or Italian, meeting abstracts, or if the researchers only performed immunohistochemistry to evaluate protein function. Two researchers (MDT and LN) independently assessed all articles based on the title, abstract, or full article. Articles for which there was disagreement regarding inclusion or exclusion were discussed and a consensus reached. The electronic search was complemented by a manual search of bibliographies from relevant articles in order to identify additional relevant studies not encountered in the electronic search. The articles that met all inclusion criteria are described in this review.

## Results

The electronic search identified 198 articles on genetic alterations in VSCC, VIN, and LS. The manual search yielded another 17 articles. 59 of these articles met the inclusion criteria and were included in this review (Tables 1 and 3). For epigenetic changes in VSCC, VIN, and LS, we found 49 articles, nine of which are included in this review (Table 4). Four articles reported on both genetic and epigenetic changes and are found in both table 1 and table 4 (28, 33-35). A flowchart illustrating the inclusion and exclusion of articles is shown in figure 1.



**Figure 1: Inclusion and exclusion of articles**

Table 1: Studies on mutations in vulvar cancer and its precursors

Author	Year	No. of patients	Diagnosis	HPV-status	Gene	Mutation %	Technique used	Remarks
<b>Pilotti</b>	1993	5	verruccous VC	-	<i>TP53</i>	0%	SSCP exon 5-9 + confirmation sequencing	
<b>Kurvinen</b>	1994	1	CIS	+	<i>TP53</i>	0%	SSCP exon 5-9 + confirmation sequencing	
		1	VIN	+	<i>TP53</i>	0%		
		2	VSCC	-	<i>TP53</i>	0%		
		7	VSCC	+	<i>TP53</i>	0%		
<b>Lee</b>	1994	9	VSCC	-	<i>TP53</i>	44%	SSCP exon 5-8 and part of exon 4	
		12	VSCC	+	<i>TP53</i>	8%		
<b>Milde-Langosch</b>	1995	12	VIN	50%*	<i>TP53</i>	33%	PCR-TGGE	* not described in association to mutations
<b>Pilotti</b>	1995	7	VIN*	+	<i>TP53</i>	0%	SSCP exon 5-9	*some adjacent to reported VSCC
		12	VSCC	-	<i>TP53</i>	33%		
		4	VSCC	+	<i>TP53</i>	50%		
<b>Kim</b>	1996	11	VSCC	-	<i>TP53</i>	36% (25% keratinising, 100% Pagets)	SSCP exon 5-8	* 11 (8 keratinising, 1 basaloid, 2 Pagets) 7 (3 keratinising, 2 basaloid, 1 Pagets, 1 warty)
<b>Slutz</b>	1997	38	VSCC	not tested	<i>TP53</i>	32%	PCR-TGGE	
<b>Wong</b>	1997	6	VSCC	not tested	<i>CDKN2A</i> and <i>CDKN2B</i>	0%	SSCP <i>CDKN2A</i> exon 1-3 and <i>CDKN2B</i> exon 1-2	
<b>Flowers</b>	1999	10*	VIN	-	<i>TP53</i>	10%		* multiple samples from same patient



	11*	VIN	+	<i>TP53</i>	9%	
	15	VSCC	-	<i>TP53</i>	29% KSC, 0% basaloid	
	15	VSCC	+	<i>TP53</i>	33% KSC, 8% basaloid	
<b>Ngan</b>	1999	25 VSCC	-	<i>TP53</i>	20%	SSCP exon 5-8 + confirmation sequencing
	23	VSCC	+	<i>TP53</i>	22%	
<b>Brooks</b>	2000	23 VSCC	-	<i>TP53</i>	74%	SSCP exon 4-9 codon 72P/R same cohort as Marin 2000 and O'Nions 2001
	13	VSCC	+	<i>TP53</i>	31%	
<b>Holway</b>	2000	2* VIN	not tested	<i>PTEN</i>	100%	SSCP exon 5-8 * same patients as VSCC
	10	VSCC	not tested	<i>PTEN</i>	60%	1 patient had <i>PTEN</i> mutation in VIN but not in adjacent VSCC. In 3 patients different mutations were found in VIN and VSCC
<b>Marin</b>	2000	36 VSCC	not tested	<i>TP53</i>	58%	SSCP exon 4-9 + confirmation sequencing
	10	LS	-	<i>TP53</i>	70%	
	29 (3 basaloid, 26 squamous)	VC	-	<i>TP53</i>	55%	
	11 (3 basaloid, 8 squamous)	VC	+	<i>TP53</i>	45%	
<b>Wada</b>	2000	1 VIN	+	<i>TP53</i> + <i>KRAS</i>	0% <i>TP53</i> , 0% <i>KRAS</i>	SSCP <i>TP53</i> exon 5-8, <i>KRAS</i> exon 1
<b>O'Nions</b>	2001	23 VSCC	-	<i>TP53</i> + <i>CDKN2A</i>	74% <i>TP53</i> , 13% <i>CDKN2A</i>	SSCP <i>CDKN2A</i> exon 1 + 2, <i>TP53</i> exon 7-9
	13	VSCC	+	<i>TP53</i> + <i>CDKN2A</i>	31% <i>TP53</i> , 0% <i>CDKN2A</i>	

<b>Gasco</b>	2002	23	VSCC	-	<i>CDKN2A</i> + <i>Stratifin</i> + <i>TP53</i>	13% <i>CDKN2A</i> , 0% <i>Stratifin</i> , 73.9 % <i>TP53</i>	<i>CDKN2A</i> and <i>stratifin</i> were tested on 11 patients
		20	VIN	-	<i>CDKN2A</i> + <i>Stratifin</i> + <i>TP53</i>	0% <i>CDKN2A</i> , 0% <i>Stratifin</i> , 0% <i>TP53</i>	<i>CDKN2A</i> and <i>stratifin</i> were tested on 11 patients
		12	VIN	+	<i>CDKN2A</i> + <i>Stratifin</i> + <i>TP53</i>	0% <i>CDKN2A</i> , 0% <i>Stratifin</i> , 0% <i>TP53</i>	<i>CDKN2A</i> and <i>stratifin</i> were tested on 11 patients
		13	VSCC	+	<i>CDKN2A</i> + <i>Stratifin</i> + <i>TP53</i>	0% <i>CDKN2A</i> , 0% <i>Stratifin</i> , 30.8% <i>TP53</i>	
<b>Rampone</b>	2002	8	LS	not tested	<i>TP53</i>	63%	Sanger sequencing exon 5-9
		10	LSC	not tested	<i>TP53</i>	0%	
<b>Reddy</b>	2002	32	VIN	not tested	<i>CHK2</i>	0% <i>CHK2</i>	
		40	VSCC	not tested	<i>CHK2</i> + <i>TP53</i>	5 % <i>CHK2</i> , 100% <i>TP53</i> *	* only tested in <i>CHK2</i> mutated samples
<b>Vanin</b>	2002	62*	LS	-	<i>TP53</i>	5%	Sanger sequencing exon 5-8 * 25 with VSCC, 37 without VSCC
		29	VSCC	-	<i>TP53</i>	28%	
<b>Rolfé</b>	2003	12	LS	not tested	<i>TP53</i>	58%	Sanger sequencing exon 5-8
		27	VSCC	not tested	<i>TP53</i>	81%	
<b>Almeida</b>	2004	2	undifferentiated VIN	-	<i>TP53</i>	50%	SCCP exon 5-8
		6	undifferentiated VIN	+	<i>TP53</i>	17%	
<b>Chulvis do Val</b>	2004	13	undifferentiated VIN	64%*	<i>TP53</i>	38%	SSCP exon 5-8 * not described in association to mutations
<b>Olawaiye</b>	2007	2	VSCC	not tested	<i>EGFR</i>	0%	Sanger sequencing exon 18-24
<b>Osakabe</b>	2007	16	VSCC	-	<i>TP53</i>	63%	SCCP exon 5-8

	5	VSCC	+	<i>TP53</i>	20%	
	7	Bowenoid early invasion and 1 invasive SCC	+	<i>TP53</i>	0%	
<b>Soufir</b>	2007	21 LS	not tested (not for all)	<i>CDKN2A</i> + <i>TP53</i>	0% <i>CDKN2A</i> , 0% <i>TP53</i>	SSCP <i>CDKN2A</i> exon 1 $\alpha$ , 1 $\beta$ and 2, <i>TP53</i> exon 4-9
	2	VIN	not tested (not for all)	<i>CDKN2A</i> + <i>TP53</i>	0% <i>CDKN2A</i> , 0% <i>TP53</i>	
	5	VSCC	not tested (not for all)	<i>CDKN2A</i> + <i>TP53</i>	20% <i>CDKN2A</i> , 60% <i>TP53</i>	
<b>Tapp</b>	2007	224 LS	not tested	<i>TP53</i> + <i>KRAS</i> (2+1 hotspot codons only)	0% had a single mutant population that exceeded 20 per 10 <sup>6</sup>	PCR/RE/LCR reports SBS single base instability (not somatic mutations, but 1 in a million errors) and only looked at 2 hotspots in <i>TP53</i> (codon 248 and 273) and 1 in <i>KRAS</i> (codon 12)
<b>Aulman</b>	2008	12 VIN (7 uVIN, 5 dVIN)	-	<i>TP53</i>	17%	SSCP exon 4-10
	20	uVIN	+	<i>TP53</i>	0%	
	24	VSCC	-	<i>TP53</i>	17%	
	4	VSCC	+	<i>TP53</i>	0%	
<b>Growdon</b>	2008	19 VSCC	-	<i>EGFR</i>	0%	Sanger sequencing exon 18-21
	22	VSCC	+	<i>EGFR</i>	0%	
	5*	CIS	not tested	<i>PTEIN</i>	60%	
<b>Pinto</b>	2010	11 VIN	-	<i>TP53</i>	60%	Sanger sequencing
	5	VSCC	-	<i>TP53</i>	80%	

<b>Choschizick</b>	2011	21 VSCC	-	<i>TP53</i>	77%	Sanger sequencing exon 5-8
		18 VSCC	+	<i>TP53</i>	24%	
<b>Janku</b>	2011	2 VSCC	not tested	<i>PIK3CA</i>	0%	Sanger sequencing c532-554 of exon 9 and c1011-1062 of exon 20
<b>Horowitz</b>	2012	17 VSCC	not tested	<i>EGFR</i>	0%	Sanger sequencing
<b>Gambichler</b>	2013	10 LS	not tested	<i>TP53, NRAS, KRAS, IDH1, IDH2, TET2</i>	0%	Sanger sequencing <i>IDH1</i> exon 4, <i>IDH2</i> exon 4, <i>TET2</i> exon 3 + 11, <i>TP53</i> exon 4,6,7, <i>KRAS</i> codon 12, <i>HRAS</i> exon 3, <i>NRAS</i> exon 2-3
		5 CIS	-	<i>EGFR</i>	0%	
		5 CIS	+	<i>EGFR</i>	0%	
<b>Trietsch</b>	2014	89 VSCC*	-	<i>BRAF, CDKN2A, CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2RIA, PTEN, and TP53</i>	0% <i>BRAF</i> , 16% <i>CDKN2A</i> , 0% <i>CTNNB1</i> , 0% <i>FBXW7</i> , 0% <i>FGFR2</i> , 0% <i>FGFR3</i> , 0% <i>FOXL2</i> , 11% <i>HRAS</i> , 1% <i>KRAS</i> , 0% <i>NRAS</i> , 8% <i>PIK3CA</i> , 3% <i>PPP2RIA</i> , 1% <i>PTEN</i> , 62% <i>TP53</i>	Hot spot mass spectrometry, Sanger sequencing <i>TP53</i> exon 5-9 *Partial overlap in VSCC patients reported in a recent article by Spaans et al. (1)

18	VSCC*	+	<p><i>BRAF</i>,  <i>CDKN2A</i>,  <i>CTNNB1</i>,  <i>FBXW7</i>,  <i>FGFR2</i>,  <i>FGFR3</i>,  <i>FOXL2</i>,  <i>HRAS</i>,  <i>KRAS</i>,  <i>NRAS</i>,  <i>PIK3CA</i>,  <i>PPP2RIA</i>,  <i>PTEN</i>, and  <i>TP53</i></p>	<p>0% <i>BRAF</i>,  0% <i>CDKN2A</i>,  0% <i>CTNNB1</i>,  0% <i>FBXW7</i>,  0% <i>FGFR2</i>,  0% <i>FGFR3</i>,  0% <i>FOXL2</i>,  0% <i>HRAS</i>,  0% <i>KRAS</i>,  0% <i>NRAS</i>,  0% <i>PIK3CA</i>,  0% <i>PPP2RIA</i>,  0% <i>PTEN</i>,  17% <i>TP53</i></p>
----	-------	---	---	--

HPV: human papillomavirus  
N: number  
LS: lichen sclerosus  
LSC: lichen sclerosus chronicans  
VSCC: vulvar squamous cell carcinoma  
VIN: vulvar intraepithelial neoplasia  
uVIN: usual vulvar intraepithelial neoplasia  
dVIN: differentiated vulvar intraepithelial neoplasia  
CIS: carcinoma in situ  
SCCP: single strand confirmation polymorphism  
PCR: polymerase chain reaction  
TGGE: temperature gradient gel electrophoresis  
KSC: keratinizing squamous carcinoma  
LCR: ligand chain reaction  
RE: restriction endonuclease

Nb. HPV status was interpreted as unknown if it was not specified for all genes tested for mutations

Table 2: Overall mutation frequencies

	LS			VIN			VSCC									
	HPV neg	HPV unknown	HPV pos	HPV pos	HPV neg	HPV unknown	HPV pos	HPV neg	HPV unknown							
<i>TP53</i>	10/72	14%	12/285	4%	2/66	3%	10/47	21%	11/29	38%	28/171	16%	109/361	30%	28/108	26%
<i>PTEN</i>									2/2	100%	0/18	0%	1/89	1%	6/10	60%
<i>EGFR</i>											0/22	0%	0/19	0%	0/19	0%
<i>BRAF</i>											0/18	0%	0/89	0%		
<i>HRAS</i>											0/18	0%	10/89	11%		
<i>KRAS</i>			0/10	0%							0/18	0%	1/89	1%		
<i>NRAS</i>			0/10	0%							0/18	0%	0/89	0%		
<i>CDKN2A</i>			0/21	0%	0/4	0%	0/2	0%	0/2	0%	0/44	0%	20/135	15%	1/11	9%
<i>CTNNB1</i>											0/18	0%	0/89	0%		
<i>PPP2R1A</i>											0/18	0%	3/89	3%		
<i>FBXW7</i>											0/18	0%	0/89	0%		
<i>PIK3CA</i>											0/18	0%	7/89	8%	0/2	0%
<i>IDH1</i>			0/10	0%												
<i>IDH2</i>			0/10	0%												
<i>TET2</i>			0/10	0%												
<i>CHK2</i>									0/32	0%					2/40	5%
<i>FGFR2</i>											0/18	0%	0/89	0%		
<i>FGFR3</i>											0/18	0%	0/89	0%		
<i>FOXL2</i>											0/18	0%	0/89	0%		
<i>Stratifin</i>					0/4	0%	0/2	0%			0/13	0%	0/23	0%		

LS: lichen sclerosus

VIN: vulvar intraepithelial hyperplasia

VSCC: vulvar squamous cell carcinoma

HPV: human papillomavirus

Nb, HPV status was interpreted as unknown if it was not specified for all genes tested for mutations

### **Somatic mutations**

A total of 34 articles were included that described somatic mutations (Table 1) (8, 25-28, 33-61). Mutations were most often studied and detected in *TP53*, with frequencies of up to 70% for LS, 60% for VIN, and 81% for vulvar cancer. *CDKN2A* mutations were not detected in LS or VIN, but occurred in 0-60% of VSCCs. Table 2 shows the overall frequencies of mutations for all included studies. HPV-negative tumors harbored more mutations than HPV-positive tumors, and the percentage of mutated samples gradually increased with higher stages of (pre)cancerous lesions.

### **Allelic imbalances, loss of heterozygosity, and copy number changes**

A total of 24 articles were included that reported allelic imbalances or copy number changes in vulvar cancer and its precursors (Table 3) (36, 45, 47-49, 51, 52, 55, 56, 58, 60, 62-73). Allelic imbalances occurred most often on chromosomes 3, 8, 11, 13, and 17. Three studies focused on the total DNA index, and each found high percentages of aneuploidy and tetraploidy (62-64). Bryndorf was the only one to test HPV infection and found the highest percentage of aneuploidy and tetraploidy in HPV-negative VSCC. Allelic imbalances were more frequently observed in higher stages of both precancerous and cancerous lesions (63).

### **Microsatellite instability**

We included three articles that reported on microsatellite instability (MSI) (65, 74, 75), a condition in which repetitive DNA sequences are susceptible to errors because the Mismatch Repair system is not functioning properly (Table 4). The articles by Bujko and Lin looked at MSI in HPV-positive and negative VSCC. Bujko et al. found no MSI in the 44 patients they investigated (29 HPV-negative and 15 HPV-positive) (74). Lin reported MSI in locus 3.1 in one of two patients with HPV-positive VSCC (65). Pinto et al. focused on MSI and allelic imbalances in uVIN, dVIN and LS, and found that MSI was confined exclusively to HPV-negative dVIN and LS lesions, but did not occur in the 15 uVINs they studied (75). The data by Pinto suggest that these molecular changes are possibly early events in the HPV-independent route of vulvar carcinogenesis, and that MSI may play a role in the malignant potential of LS. However, in a small cohort of 4 patients with VSCC described by Lin et al., 2 patients with HPV-positive tumors displayed MSI as well. These data indicate that the exact role of MSI in vulvar carcinogenesis needs to be elucidated.

Table 3: Studies on allelic imbalances in vulvar cancer and its precursors

Author	Year	No. of patients	Diagnosis	HPV-status	Gene/locus	AI %	loss or gain	Technique used	Remarks
Wong	1997	6	VSCC	not tested	<i>CDKN2A</i> and <i>CDKN2B</i>	50% <i>CDKN2A</i> , 50% <i>CDKN2B</i>	loss	LOH	
	Lin	1998	2	VIN	-	0% 1.2,	loss	LOH	
						0% 2.3,			
						50% 2.4,			
						0% 3.1,			
						0% 3.4,			
						0% 4.1,			
						50% 5.2,			
						50% 5.3,			
						0% 8.2,			
0% 21.1									
Lin	1998	2	VIN	+	0% 1.2,	loss			
					50% 2.3,				
					50% 2.4,				
					0% 3.1,				
					50% 3.4,				
					0% 4.1,				
					0% 5.2,				
					0% 5.3,				
					50% 8.2,				
					0% 21.1				
Lin	1998	2	VSCC	-	0% 1.2,	loss			
					100% 2.3,				
					100% 2.4,				
					50% 3.1,				
					50% 3.4,				
					50% 4.1,				
					100% 5.2,				
					50% 5.3,				
					50% 8.2,				
					50% 21.1				



		2	VSCC	+		50% 1.2, 0% 2.3, 100% 2.4, 0% 3.1, 0% 3.4, 0% 4.1, 0% 5.2, 100% 5.3, 50% 8.2, 0% 21.1	loss		
<b>Flowers</b>	1999	10*	VIN	-	3p chromosomal regions (3p 12, 3pl 4.2, 3pl 4.3- 21.1, 3p21.3, 3p22-24, 3p24.3, 3p25), 13q14 ( <i>RB</i> ) and 17p13.1 ( <i>TP53</i> ) loci	54% 3p, 14% 13q ( <i>RB</i> ), 9% 17p ( <i>TP53</i> )	loss	LOH	* multiple samples from same patients
		10*	VIN	+	3p chromosomal regions (3p 12, 3pl 4.2, 3pl 4.3- 21.1, 3p21.3, 3p22-24, 3p24.3, 3p25), 13q14 ( <i>RB</i> ) and 17p13.1 ( <i>TP53</i> ) loci	16% 3p, 6% 13q ( <i>RB</i> ), 0% 17p ( <i>TP53</i> )	loss		
		15	VSCC	-	3p chromosomal regions (3p 12, 3pl 4.2, 3pl 4.3- 21.1, 3p21.3, 3p22-24, 3p24.3, 3p25), 13q14 ( <i>RB</i> ) and 17p13.1 ( <i>TP53</i> ) loci	93% 3p, 27% 13q ( <i>RB</i> ), 62% 17p ( <i>TP53</i> )	loss		
		15	VSCC	+	3p chromosomal regions (3p 12, 3pl 4.2, 3pl 4.3- 21.1, 3p21.3, 3p22-24, 3p24.3, 3p25), 13q14 ( <i>RB</i> ) and 17p13.1 ( <i>TP53</i> ) loci	67% 3p, 31% 13q ( <i>RB</i> ), 15% 17p ( <i>TP53</i> )	loss		

Scheistroen	1999	167 VSCC	not tested	77% diploid, 23% aneuploid	EACS
<b>Pinto</b>	1999	8 VSCC	-	Overall 36% LOH. Most frequent: 83% 5q, 100% 10p, 29% 1p, 25% 2q, 50% 3p, 63% 8p, 63% 8q, 60% 10q, 50% 11q, 29% 15q, 80% 17p, 50% 21q, 60% 22q.	LOH
		8 VSCC	+	Overall 30% LOH. Most frequent: 13% 5q, 17% 10q, 33% 1p, 0% 2q, 50% 3p, 13% 5q, 33% 8p, 50% 8q, 17% 10p, 25% 11q, 43% 15q, 43% 17p, 67% 21q, 20% 22q.	loss

<b>Pinto</b>	2000	16 VIN (5 uVIN, 11 dVIN)	-	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	15%*	both	LOH	*scoring informative (heterozygous) loci
		14 VIN (10 uVIN, 4 dVIN)	+	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	25%*	both		*scoring informative (heterozygous) loci
		17 LS	-	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	10%*	both		*scoring informative (heterozygous) loci
<b>Brooks</b>	2000	23 VSCC	-	<i>TP53</i>	61%	loss	LOH	codon 72PR same cohort as Marin 2000 and O'Nion 2001
<b>Carlson</b>	2000	13 VSCC	+	<i>TP53</i>	54%	loss		
		12 LS	not tested	chr 17	chr 17 aneusomy: 100%. DNA index aneuploidy: 58%		FISH	
		3 VIN	not tested	chr 17	chr 17 aneusomy: 100% DNA index aneuploidy: 67%			
		14* VSCC	not tested	chr 17	chr 17 aneusomy: 93% DNA index aneuploidy: 86%			* 10 SCC, 4 SCCIS
<b>Marin</b>	2000	36 VSCC	not tested	<i>TP53</i>	54%	loss	LOH	
<b>Wada</b>	2000	1 VIN	+	3p14.2, 3p, 9p21, 9p23, 13q22, 17p12	0%	loss	LOH	

<b>Jee</b>	2001	10 VSCC	not tested	DNA copy number changes in 80%.	both	CGH
				Loss: 50% 4p13-pter, 40% 3p, 10% 5q14-q23, 10% 6q11-q16, 10% 11q21-qter, 10% 13q14-q32. Gain: 40% 3q, 30% 8q, 10% 9p, 10% 14, 10% 17, 10% 20q		
<b>Rosenthal</b>	2001	13 VSCC	-	LOH of 48% 17p, 40% 9p, 48% 3p, 44% 4q, 43% 5p, 44% 11p	loss	
		54 VSCC	+	LOH of 48% 17p, 40% 9p, 48% 3p, 44% 4q, 43% 5p, 44% 11p	loss	
<b>Allen</b>	2002	8 VSCC	-	Most common: 75% 8q gain, 0% 3q gain, 13% 3p loss, 50% 11q loss	both	CGH

	10	VSCC	+			Most common 20% 8q gain, 50% 3q gain, 40% 3p loss, 40% 11q loss	both	
<b>Reddy</b>	2002	32 VIN	not tested	<i>CHK2</i>	0%*			
		40 VSCC	not tested	<i>CHK2</i>	2%*		loss	direct sequencing of RT-PCR product * only tested in <i>CHK2</i> mutated samples
<b>Vanin</b>	2002	62* LS	-	<i>TP53</i>	0%		loss	LOH * 25 with VSCC, 37 without VSCC
<b>Bryndorf</b>	2004	29 VSCC	-	<i>TP53</i>	74%		loss	
		4 condyloma	-		0	chromosomal abberations	both	hrCGH and FACS
		2 VIN	-		100%	diploid. Most common gain of: 0% chr 1, 0% 3q, 0% 20q, 0% 20p, 0% 3q, 0% 8q. Loss of 0% 3p, 0% 8p.	both	

9	VIN	+	both	<p>40% diploid,            30% aneuploid,            30% tetraploid.            Most common gain of:            60% chr 1,            50% 3q,            50% 20q,            40% 20p,            30% 8q.            Loss of            20% 3p,            0% 8p</p>
6	VSCC	-	both	<p>25% diploid,            75% aneuploid.            Most common gain of:            0% chr 1,            75% 3q,            50% 20q,            50% 20p,            100% 8q.            Loss of            50% 3p,            50% 8p</p>
4	VSCC	+	both	<p>50% diploid,            50% tetraploid.            Most common gain of:            0% chr 1,            66% 3q,            17% 20q,            17% 20p,            33% 8q.            Loss of            83% 3p,            33% 8p</p>

<b>Huang</b>	2005	8 VSCC	75%*		gains of 1q 13%, 3q 38%, 5p 38%, 8q 75%. Losses 3p 38%, 4p 13%, 11p 13%	both	CGH	* not described in association to genetic changes
<b>Olawaiye</b>	2007	2 VSCC	not tested	<i>EGFR</i>	0%		q rtPCR	
<b>Osakabe</b>	2007	16 VSCC	-		LOH of 44% 3p14.2 ( <i>FHIT</i> ), 38% 3p26 ( <i>VHL</i> ), 38% 5q31 ( <i>APC</i> ), 63% 9q21 ( <i>p16</i> ), 67% 9q22.3 ( <i>PTECH</i> ), 38% 10p15 ( <i>PAHX</i> ), 30% 13q14.3-21.1 ( <i>Rb</i> ), 40% 17p13 ( <i>TP53</i> ), 44% 18q21 ( <i>DCC</i> ). Fractional allelic loss 43%	loss	LOH	
		5 VSCC	+		LOH of 50% 3p14.2 ( <i>FHIT</i> ), 100% 9q21 ( <i>p16</i> ), 50% 9q22.3 ( <i>PTCH</i> ). Fractional allelic loss 18%	loss		
<b>Yangling</b>	2007	10 VSCC	-	3q, 3p, 4p, 8q, 12q	Gain: 10% 3q, 70% 8q, 0% 12q. Loss: 40% 3p, 50% 4p	both	CGH	

	11	VSCC	+	3q, 3p, 4p, 8q, 12q	both	Gain: 73% 3q, 64% 12q, 9% 8q; Loss: 46% 3p, 55% 4p	
<b>Growdon</b>	2008	19	VSCC	-	<i>EGFR + HER2</i>	32% <i>EGFR</i> , 0% <i>HER2</i> , 16% polysomy chr 7	gene amplification FISH
		22	VSCC	+	<i>EGFR + HER2</i>	0% <i>EGFR</i> , 0% <i>HER2</i>	
		5	CIS	-	<i>EGFR + HER2</i>	0% <i>EGFR</i> , 0% <i>HER2</i>	
		5	CIS	+	<i>EGFR + HER2</i>	0% <i>EGFR</i> , 0% <i>HER2</i>	
<b>Aulman</b>	2008	12	VIN (7 uVIN, 5 dVIN)	-	3q26	73%	gain FISH
		20	uVIN	+	3q26	50%	gain
		24	VSCC	-	3q26	83%	gain
		4	VSCC	+	3q26	75%	gain
<b>Horowitz</b>	2012	17	VSCC	not tested	<i>EGFR</i>	12%	gene amplification FISH
<b>Lavorato-Rocha</b>	2013	139	VSCC	33%*	7P53	65% normal gene / chr copy number, 19% polysomy, 9% monosomy, 6% deletion	both FISH * not described in association to genetic changes



Mircci	2013	14 VSCC	not tested	Amongst others <i>FHIT, PTPRD</i>	both	arrayCGH + rtPCR + karyotyping
HPV:	human papillomavirus					
N:	number					
LS:	lichen sclerosus					
LSC:	lichen sclerosus chronicans					
SCC:	vulvar squamous cell carcinoma					
VIN:	vulvar intraepithelial neoplasia					
AI:	allelic imbalance					
LOH:	loss of heterozygosity					
FISH:	fluorescence in situ hybridization					
RT-PCR:	real time polymerase chain reaction					
(hr)CGH:	(high resolution) comparative genomic hybridization					
FACS:	fluorescence-activated cell sorting					
SCCIS:	squamous cell carcinoma in situ					
	Nb. HPV status was interpreted as unknown if it was not specified for all genes tested for allelic imbalances					
					70% aneuploid, 20% tetraploid, 10% diploid. 90% array-CGH imbalances. Loss of a region of 64% 8p23.1, 57% 8p21.3, 57% 8p12, 50% 3p14.2, 50% 3p13, 50% 8p23.3-p23.1, 50% 8p23.1-p11.23, 50% 8p11.22-p11.1, 50% 8q23.3, 50% 8q24.12-q24.22, 50% 9p23. Homozygous deletion of 29% p23 ( <i>PTPRD</i> ). No common amplified region.	

**Table 4: Studies on microsatellite instability (MSI) in vulvar cancer and its precursors**

Author	Year	No. of patients	Diag-nosis	HPV-status	Locus	% MSI	Technique used
Lin	1998	2	VSCC	-	3.1	0%	PCR
		2	VSCC	+	3.1	50%	
Bujko	2012	29	VSCC	-		0%	PCR
		15	VSCC	+		0%	
Pinto	2000	5	uVIN	-	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	0%	PCR
		10	uVIN	+	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	0%	
		11	dVIN	-	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	27%	
		4	dVIN	+	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	0%	
		17	LS	-	3p, 5q, 8p, 8q, 10p, 10q, 11q, 17p, 18q, 21q, 22q	12%	

HPV: human papillomavirus

LS: lichen sclerosus

VSCC: vulvar squamous cell carcinoma

VIN: vulvar intraepithelial neoplasia

PCR: polymerase chain reaction

### Epigenetic alterations

Nine articles were included that reported on epigenetic alterations in VSCC or its precursors (Table 5) (28-30, 33, 34, 76-79). *CDKN2A* was studied most often (28-30, 33, 34, 76, 78, 79). *CDKN2A* is more frequently hypermethylated in VSCC (up to 68%) and VIN (up to 72%) than in LS (up to 47%), but there is great variability in the reported frequencies. An overview of all genes tested for hypermethylation and the percentage of hypermethylation is shown in table 6. When HPV status was not specified for all genes tested for hypermethylation, HPV status was interpreted as unknown.

Table 5: Studies on hypermethylation in vulvar cancer and its precursors

Author	Year	No. of patients	Diag-nosis	HPV-status	Gene	% Hypermethylation	Technique used	Remarks
O'Nions	2001	13	VSCC	HPV 16 +	<i>CDKN2A</i>	15,4%	msPCR	
			VSCC	HPV 16 -	<i>CDKN2A</i>	47,8%	msPCR	
Gasco	2002	0	VIN 1	HPV 16 +	<i>Stratifin, CDKN2A</i>	0% <i>Stratifin</i> , 0% <i>CDKN2A</i>	msPCR	
			VIN 1	HPV 16 -	<i>Stratifin, CDKN2A</i>	0% <i>Stratifin</i> , 0% <i>CDKN2A</i>	msPCR	
		1	VIN 2	HPV 16 +	<i>Stratifin, CDKN2A</i>	0% <i>Stratifin</i> , 0% <i>CDKN2A</i>	msPCR	
		5	VIN 2	HPV 16 -	<i>Stratifin, CDKN2A</i>	40% <i>Stratifin</i> , 40% <i>CDKN2A</i>	msPCR	
		11	VIN 3	HPV 16 +	<i>Stratifin, CDKN2A</i>	45,5% <i>Stratifin</i> , 9,1% <i>CDKN2A</i>	msPCR	
		11	VIN 3	HPV 16 -	<i>Stratifin, CDKN2A</i>	72,7% <i>Stratifin</i> , 72,7% <i>CDKN2A</i>	msPCR	
		13	VSCC	HPV 16 +	<i>Stratifin, CDKN2A</i>	53,8% <i>Stratifin</i> , 15,4% <i>CDKN2A</i>	msPCR	
		23	VSCC	HPV 16 -	<i>Stratifin, CDKN2A</i>	56,5% <i>Stratifin</i> , 47,8% <i>CDKN2A</i>	msPCR	
Lerma	2002	21	LS	not tested	<i>CDKN2A</i>	42,8%	ms-PCR	
			9 uVIN, 4 dVIN	not tested	<i>CDKN2A</i>	69,2%	ms-PCR	
		38	VSCC	not tested	<i>CDKN2A</i>	68%	ms-PCR	

<b>Soufir</b>	2007	2	LS	HPV 16 +	<i>CDKN2A, p14</i>	0% <i>CDKN2A</i> , 0% <i>p14</i>	ms-PCR
		8	LS	HPV 16 -	<i>CDKN2A, p14</i>	12,5% <i>CDKN2A</i> , 0% <i>p14</i>	ms-PCR
		2	VIN3	HPV 16 +	<i>CDKN2A, p14</i>	0% <i>CDKN2A</i> , 0% <i>p14</i>	ms-PCR
		2	VSCC	HPV 16 +	<i>CDKN2A, p14</i>	0% <i>CDKN2A</i> , 0% <i>p14</i>	ms-PCR
		2	VSCC	HPV 16 -	<i>CDKN2A, p14</i>	0% <i>CDKN2A</i> , 0% <i>p14</i>	ms-PCR
<b>Aide</b>	2010	15	LS	not tested	<i>DAPK + CDKN2A</i>	13% <i>DAPK</i> , 47% <i>CDKN2A</i>	ms-PCR
<b>Guerrero</b>	2011	21	LS not associated with VSCC	HPV + 25%	<i>RASSF1A, RASSF2A, CDKN2A, TSP-1 and MGMT</i>	52,4% <i>RASSF1A</i> , 0% <i>RASSF2A</i> , 19% <i>CDKN2A</i> , 52,4% <i>TSP-1</i> , 0% <i>MGMT</i>	ms-PCR 25% HPV positive, but HPV status not specified per gene investigated for hypermethylation
		12	LS associated with VSCC	not tested	<i>RASSF1A, RASSF2A, CDKN2A, TSP-1 and MGMT</i>	33,3% <i>RASSF1A</i> , 8,3% <i>RASSF2A</i> , 16,6% <i>CDKN2A</i> , 50% <i>TSP-1</i> , 41,7% <i>MGMT</i>	ms-PCR
		1	VSCC	HPV +	<i>RASSF1A, RASSF2A, CDKN2A, TSP-1 and MGMT</i>	0% <i>RASSF1A</i> , 0% <i>RASSF2A</i> , 0% <i>CDKN2A</i> , 20% <i>TSP-1</i> , 0% <i>MGMT</i>	ms-PCR TSP-1 hypermethylation was tested on 5 patients
		11	VSCC	HPV -	<i>RASSF1A, RASSF2A, CDKN2A, TSP-1 and MGMT</i>	45,5% <i>RASSF1A</i> , 72,7% <i>RASSF2A</i> , 54,5% <i>CDKN2A</i> , 40% <i>TSP-1</i> , 72,7% <i>MGMT</i>	ms-PCR TSP-1 hypermethylation was tested on 25 patients

<b>Aide</b>	2012	23	LS	not tested	<i>DAPK</i> + <i>CDKN2A</i>	17% <i>DAPK</i> , 35% <i>CDKN2A</i>	ms-PCR
<b>Oonk</b>	2012	20	VSCC	not tested	<i>CDKN2A</i> , <i>MGMT</i> , <i>TWIST1</i> , <i>CADM1</i> , <i>TERT</i> and <i>TFPI2</i>	65% <i>CDKN2A</i> , 45% <i>MGMT</i> , 35% <i>TWIST1</i> , 55% <i>CADM1</i> , 100% <i>TERT</i> , 60% <i>TFPI2</i>	msPCR
<b>Guerrero</b>	2013	21	LS	HPV + 25%	<i>TSLC-1</i>	25% <i>TSLC-1</i>	ms-PCR
		30	VSCC	16,7% +	<i>TSLC-1</i>	44,4% <i>TSLC-1</i>	ms-PCR

HPV: human papillomavirus

LS: lichen sclerosus

LSC: lichen sclerosus chronicans

VSCC: vulvar squamous cell carcinoma

VIN: vulvar intraepithelial neoplasia

msPCR: methylation-specific polymerase chain reaction

Nb. HPV status was interpreted as unknown if it was not specified for all genes tested for hypermethylation

25% HPV positive, but HPV status not specified per gene investigated for hypermethylation

Same cohort as Guerrero 2011. Only new results are described here.

Table 6: Overall hypermethylation frequencies

	LS				VIN				VSCC							
	HPV pos	HPV neg	HPV unknown	HPV pos	HPV neg	HPV unknown	HPV pos	HPV neg	HPV unknown	HPV pos	HPV neg	HPV unknown				
<i>CDKN2A</i>	0/2	1/8	26/92	28,3%	1/14	7,1%	10/20	50%	9/13	69,2%	4/29	13,8%	28/59	47,5%	39/58	67,2%
<i>p14</i>	0/2	0/8	0%	0/2	0%	0/2	0%	0/2	0%	0/2	0%	0/2	0%	0/2	0%	0%
<i>DAPK</i>			6/38	15,8%												
<i>MGMT</i>			0/33	0%											9/20	45%
<i>TWIST1</i>															7/20	35%
<i>CADMI</i>															11/20	55%
<i>TERT</i>															20/20	100%
<i>TFPI2</i>															12/20	60%
<i>RASSF1A</i>							15/33	45,5%								
<i>RASSF2A</i>							1/33	3,0%								
<i>TSP-1</i>							17/33	51,5%								
<i>Stratifin</i>							5/12	41,7%	10/20	50%	7/13	53,8%	11/23	56,5%		
<i>TSLC-1</i>							9/21	42,9%							11/30	44,4%

LS: lichen sclerosus

VIN: vulvar intraepithelial hyperplasia

VSCC: vulvar squamous cell carcinoma

HPV: human papillomavirus

Nb, HPV status was interpreted as unknown if it was not specified for all genes tested for hypermethylation

## Discussion

A growing body of research has focused on genetic and epigenetic changes in vulvar cancer. The combined results of the currently available literature on genetic and epigenetic changes confirm the hypothesis that HPV and *TP53* mutations play almost separate, but key roles in the carcinogenesis of VSCC (Table 5). Patients infected with HPV are less likely to carry somatic mutations than patients without HPV, but allelic imbalances seem to occur in both groups. The cumulative number of genetic changes increases with increasing grade of dysplasia and cancer stage. Although only a few studies have sufficient numbers of patients to perform survival analysis related to genetic and epigenetic changes, the findings suggest that tumors harboring a mutation, which are most often HPV-independent VSCC, have a worse prognosis than VSCC without (epi) genetic changes (36, 43, 50, 54, 58, 62, 73, 80).

The frequencies of detected mutations vary between studies. These differences can be explained, in part, by the composition of the cohorts. The included cohorts may vary in terms of age and ethnic background or tumor stage, which is known to be related to genetic alterations. Also, differences in the techniques used and coverage of the screened exons may play a role. Detection methods have improved over the last few decades, which is reflected in an overall increase in the number of detected *TP53* mutations within HPV-negative tumor samples.

The amount of research on epigenetic changes in VSCC and its precursors is limited, but studies in other types of cancer have shown the importance of these tumor characteristics in the development of targeted therapy (81). We only found articles on hypermethylation. In our literature search we did not find any articles on other possible epigenetic changes in VSCC or its precursors, such as chromatin remodeling or histone modifications. Most research on hypermethylation has studied different genes so a comparison cannot be made. Only *CDKN2A* has been investigated by more than one group. The hypermethylation frequencies that were found differ greatly between LS, VIN, and VSCC. The trend appears to be more hypermethylation in VSCC, but with the limited data it is difficult to draw any conclusions. With the fast development of research techniques focusing on epigenetic alterations in tumors, and the knowledge already gained on targeted therapy for epigenetically altered tumors, future research on this topic is promising.

In conclusion, genetic and epigenetic changes are detected more often with increasing precursor and tumor stage, and are more frequently found in HPV-negative patients than HPV-positive patients. However, compared to other types of cancer, studies on genetic and epigenetic changes in vulvar cancer and its precursors is relatively few and,

therefore, our knowledge on this subject is still limited. Most genetic studies focus on HPV infection and TP53 mutations, , the latter being the most frequent genetic change found in human cancers so far. Recent studies provide evidence that somatic mutations often do occur in other genes, such as CDKN2A and HRAS. Of all premalignant and malignant vulvar lesions, HPV-independent VSCC represents the largest group of patients with the worst prognosis and most difficulties in the diagnosis and treatment of progressive tumors. The upcoming availability of screening methods for somatic mutations that provide information on the complete or very large parts of the genome, such as next generation sequencing, may provide us with more insight into the mutational and epigenetic landscape and the etiology of vulvar cancer. Hopefully, these advances will increase future treatment possibilities and improve prognosis.

**Conflict of interest statement**

There are no conflicts of interest.



## References

1. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. *Histopathology*. 2013;62(1):161-75.
2. Gadducci A, Tana R, Barsotti C, Guerrieri ME, Genazzani AR. Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. *Crit RevOncolHematol*. 2012;83(1):71-83.
3. van der Avoort IA, Shirango H, Hoevenaars BM, Grefte JM, de Hullu JA, de Wilde PC, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. *IntJGynecolPathol*. 2006;25(1):22-9.
4. Schuurman MS, van den Einden LC, Massuger LF, Kiemenev LA, van der Aa MA, de Hullu JA. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. *EurJCancer*. 2013;49(18):3872-80.
5. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, Bekkers RL, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. *EurJCancer*. 2009;45(5):851-6.
6. McCluggage WG. Premalignant lesions of the lower female genital tract: cervix, vagina and vulva. *Pathology*. 2013;45(3):214-28.
7. Raspollini MR, Asirelli G, Moncini D, Taddei GL. A comparative analysis of lichen sclerosus of the vulva and lichen sclerosus that evolves to vulvar squamous cell carcinoma. *AmJObstetGynecol*. 2007;197(6):592-5.
8. Pinto AP, Miron A, Yassin Y, Monte N, Woo TY, Mehra KK, et al. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. *ModPathol*. 2010;23(3):404-12.
9. Hantschmann P, Sterzer S, Jeschke U, Friese K. P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. *Anticancer Res*. 2005;25(3A):1739-45.
10. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. *Obstet Gynecol*. 2005;106(6):1319-26.
11. Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. *ObstetGynecol*. 1994;84(5):741-5.
12. Rolfe KJ, Eva LJ, MacLean AB, Crow JC, Perrett CW, Reid WM. Cell cycle proteins as molecular markers of malignant change in vulvar lichen sclerosus. *IntJGynecolCancer*. 2001;11(2):113-8.
13. Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? *IntJGynecolCancer*. 2011;21(7):1297-305.
14. Gonzalez BJ, Magrina JF, Gaffey TA, Hernandez JL, Webb MJ, Cliby WA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. *GynecolOncol*. 2005;97(3):828-33.

15. Coulter J, Gleeson N. Local and regional recurrence of vulvar cancer: management dilemmas. *Best Pract Res Clin Obstet Gynaecol.* 2003;17(4):663-81.
16. Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L. Groin recurrence in carcinoma of the vulva: management and outcome. *EurJCancer Care (Engl).* 2010;19(3):302-7.
17. Hopkins MP, Reid GC, Morley GW. The surgical management of recurrent squamous cell carcinoma of the vulva. *Obstet Gynecol.* 1990;75(6):1001-5.
18. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. *ProcNatlAcadSciUSA.* 2008;105(25):8713-7.
19. Gasche JA, Goel A. Epigenetic mechanisms in oral carcinogenesis. *FutureOncol.* 2012;8(11):1407-25.
20. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. *GynecolOncol.* 2013;128(3):409-14.
21. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. *Breast Cancer Res Treat.* 2012;134(1):333-43.
22. Wegman P, Ahlin C, Sorbe B. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. *IntJGynecolCancer.* 2011;21(1):86-91.
23. Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. *ArchOtolaryngolHead Neck Surg.* 2006;132(6):668-77.
24. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *NEnglJMed.* 2011;364(26):2507-16.
25. Choschzick M, Hantaredja W, Tennstedt P, Giesecking F, Wolber L, Simon R. Role of TP53 mutations in vulvar carcinomas. *Int J Gynecol Pathol.* 2011;30(5):497-504.
26. Rolfé KJ, MacLean AB, Crow JC, Benjamin E, Reid WM, Perrett CW. TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva. *BrJCancer.* 2003;89(12):2249-53.
27. Holway AH, Rieger-Christ KM, Miner WR, Cain JW, Dugan JM, Pezza JA, et al. Somatic mutation of PTEN in vulvar cancer. *ClinCancer Res.* 2000;6(8):3228-35.
28. Soufir N, Queille S, Liboutet M, Thibaudeau O, Bachelier F, Delestaing G, et al. Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors. *BrJDermatol.* 2007;156(3):448-53.
29. Aide S, Lattario FR, Almeida G, do Val IC, Carvalho MG. Promoter hypermethylation of death-associated protein kinase and p16 genes in vulvar lichen sclerosus. *JLow Genit TractDis.* 2012;16(2):133-9.
30. Guerrero D, Guarch R, Ojer A, Casas JM, Mendez-Meca C, Esteller M, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. *IntJCancer.* 2011;128(12):2853-64.
31. Kelemen LE, Kobel M, Chan A, Taghaddos S, Dinu I. Differentially Methylated Loci Distinguish Ovarian Carcinoma Histological Types: Evaluation of a DNA Methylation Assay in FFPE Tissue. *BiomedResInt.* 2013;2013:815894.

32. Smith ZD, Chan MM, Mikkelsen TS, Gu H, Gnirke A, Regev A, et al. A unique regulatory phase of DNA methylation in the early mammalian embryo. *Nature*. 2012;484(7394):339-44.
33. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, et al. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. *Oncogene*. 2002;21(12):1876-81.
34. O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, et al. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. *Br J Cancer*. 2001;85(10):1551-6.
35. Gambichler T, Terras S, Kreuter A, Skrygan M. Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus - further support for epigenetic mechanisms. *Br J Dermatol*. 2013.
36. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, et al. Decreased survival in EGFR gene amplified vulvar carcinoma. *Gynecol Oncol*. 2008;111(2):289-97.
37. Pilotti S, Donghi R, D'Amato L, Giarola M, Longoni A, Della TG, et al. HPV detection and p53 alteration in squamous cell verrucous malignancies of the lower genital tract. *Diagn MolPathol*. 1993;2(4):248-56.
38. Kurvinen K, Tervahauta A, Syrjanen S, Chang F, Syrjanen K. The state of the p53 gene in human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing. *Anticancer Res*. 1994;14(1A):177-81.
39. Lee YY, Wilczynski SP, Chumakov A, Chih D, Koeffler HP. Carcinoma of the vulva: HPV and p53 mutations. *Oncogene*. 1994;9(6):1655-9.
40. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. *Int J Cancer*. 1995;63(5):639-45.
41. Pilotti S, D'Amato L, Della TG, Donghi R, Longoni A, Giarola M, et al. Papillomavirus, p53 alteration, and primary carcinoma of the vulva. *Diagn MolPathol*. 1995;4(4):239-48.
42. Kim YT, Thomas NF, Kessid TD, Wilkinson EJ, Hedrick L, Cho KR. p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. *HumPathol*. 1996;27(4):389-95.
43. Sliutz G, Schmidt W, Tempfer C, Speiser P, Gitsch G, Eder S, et al. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis. *Gynecol Oncol*. 1997;64(1):93-8.
44. Wong YF, Chung TK, Cheung TH, Nobori T, Yim SF, Lai KW, et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. *Gynecol Oncol*. 1997;65(2):319-24.
45. Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, et al. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. *J Soc Gynecol Investig*. 1999;6(4):213-21.
46. Ngan HY, Cheung AN, Liu SS, Yip PS, Tsao SW. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. *Eur J Cancer*. 1999;35(3):481-4.

47. Brooks LA, Tidy JA, Gusterson B, Hiller L, O’Nions J, Gasco M, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. *Cancer Res.* 2000;60(24):6875-7.
48. Marin MC, Jost CA, Brooks LA, Irwin MS, O’Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. *Nature Genetics.* 2000;25(1):47-54.
49. Wada H, Enomoto T, Yoshino K, Ozaki K, Kurachi H, Nomura T, et al. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia. *Am J Clin Pathol.* 2000;114(3):371-9.
50. Rampone A, Vozza G, Vozza A, Rampone B, Capuano I, Tirabasso S, et al. Lichen and vulvar cancer. Personal experience. [Italian] I lichen ed il carcinoma vulvare. Nostra esperienza. *Giornale Italiano di Dermatologia e Venereologia.* 2002;137(4):267-9.
51. Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy JA, et al. Analysis of CHK2 in vulvar neoplasia. *Br J Cancer.* 2002;86(5):756-60.
52. Vanin K, Scurry J, Thorne H, Yuen K, Ramsay RG. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer. *J Invest Dermatol.* 2002;119(5):1027-33.
53. Almeida G, do V, I, Gondim C, Lima R, Takiya C, Carvalho G. Human papillomavirus, Epstein-Barr virus and p53 mutation in vulvar intraepithelial neoplasia. *J ReprodMed.* 2004;49(10):796-9.
54. Chulvis do Val IC, Almeida Filho GL, Valiante PM, Gondim C, Takiya CM, Carvalho MG. Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. *J ReprodMed.* 2004;49(11):868-74.
55. Olawaiye A, Lee LM, Krasner C, Horowitz N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. *Gynecologic Oncology.* 2007;106(3):628-30.
56. Osakabe M, Hayashi M, Katayama Y, Emura I, Nemoto K, Umezu H, et al. Characteristics of vulvar squamous cell carcinoma in Japanese women. *PatholInt.* 2007;57(6):322-7.
57. Tapp RA, Feng J, Jones JW, Carlson JA, Wilson VL. Single base instability is promoted in vulvar lichen sclerosus. *J Invest Dermatol.* 2007;127(11):2563-76.
58. Aulmann S, Schleibaum J, Penzel R, Schirmacher P, Gebauer G, Sinn HP. Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. *J Clin Pathol.* 2008;61(9):1034-7.
59. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. *Molecular Cancer Therapeutics.* 2011;10(3):558-65.
60. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. *Gynecol Oncol.* 2012;127(1):141-6.
61. Trietsch MD, Spaans VM, ter Haar NT, Osse EM, Peters AA, Gaarenstroom KN, et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. *GynecolOncol.* 2014;135(1):149-55.
62. Scheistroen M, Trope C, Pettersen EO, Nesland JM. p53 protein expression in squamous cell carcinoma of the vulva. *Cancer.* 1999;85(5):1133-8.

63. Bryndorf T, Kirchoff M, Larsen J, Andreasson B, Bjerregaard B, Westh H, et al. The most common chromosome aberration detected by high-resolution comparative genomic hybridization in vulvar intraepithelial neoplasia is not seen in vulvar squamous cell carcinoma. *CytogenetGenome Res.* 2004;106(1):43-8.
64. Micci F, Panagopoulos I, Haugom L, Dahlback H-S, Pretorius ME, Davidson B, et al. Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. *Genes Chromosomes and Cancer.* 2013;52(6):551-63.
65. Lin MC, Mutter GL, Trivijisilp P, Boynton KA, Sun D, Crum CP. Patterns of allelic loss (LOH) in vulvar squamous carcinomas and adjacent noninvasive epithelia. *AmJPathol.* 1998;152(5):1313-8.
66. Pinto AP, Lin M-C, Mutter GL, Sun D, Villa LL, Crum CP. Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas. *American Journal of Pathology.* 1999;154(4):1009-15.
67. Carlson JA, Healy K, Tran TA, Malfetano J, Wilson VL, Rohwedder A, et al. Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. *American Journal of Pathology.* 2000;157(3):973-83.
68. Jee KJ, Kim YT, Kim KR, Kim HS, Yan A, Knuutila S. Loss in 3p and 4p and gain of 3q are concomitant aberrations in squamous cell carcinoma of the vulva. *Modern Pathology.* 2001;14(5):377-81.
69. Allen DG, Hutchins AM, Hammet F, White DJ, Scurry JP, Tabrizi SN, et al. Genetic aberrations detected by comparative genomic hybridisation in vulvar cancers. *BrJCancer.* 2002;86(6):924-8.
70. Rosenthal AN, Ryan A, Hopster D, Suretheran T, Jacobs IJ. High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). *IntJCancer.* 2001;94(6):896-900.
71. Huang FY, Kwok YKY, Lau ET, Tang MHY, Ng TY, Ngan HYS. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. *Cancer Genetics and Cytogenetics.* 2005;157(1):42-8.
72. Yangling O, Shulang Z, Rongli C, Bo L, Lili C, Xin W. Genetic imbalance and human papillomavirus states in vulvar squamous cell carcinomas. *European Journal of Gynaecological Oncology.* 2007;28(6):442-6.
73. Lavorato-Rocha AM, De Melo MB, Rodrigues IS, Stiepcich MMA, Baiocchi G, Cestari FMDS, et al. Prognostication of vulvar cancer based on p14ARF status: Molecular assessment of transcript and protein. *Annals of Surgical Oncology.* 2013;20(1):31-9.
74. Bujko M, Kowalewska M, Zub R, Radziszewski J, Bidzinski M, Siedlecki JA. Lack of microsatellite instability in squamous cell vulvar carcinoma. *Acta Obstet Gynecol Scand.* 2012;91(3):391-4.
75. Pinto AP, Lin MC, Sheets EE, Muto MG, Sun D, Crum CP. Allelic imbalance in lichen sclerosis, hyperplasia, and intraepithelial neoplasia of the vulva. *GynecolOncol.* 2000;77(1):171-6.
76. Aide S, Lattario FR, Almeida G, do Val IC, Carvalho MG. Promoter hypermethylation patterns of death-associated protein kinase and p16 genes in vulvar lichen sclerosis. *J Low GenitTract Dis.* 2010;14(4):282-6.
77. Guerrero-Setas D, Perez-Janices N, Ojer A, Blanco-Fernandez L, Guarch-Troyas C, Guarch R. Differential gene hypermethylation in genital lichen sclerosis and cancer: a comparative study. *Histopathology.* 2013;63(5):659-69.

78. Lerma E, Esteller M, Herman JG, Prat J. Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. *HumPathol.* 2002;33(11):1120-5.
79. Oonk MH, Eijssink JJ, Volders HH, Hollema H, Wisman GB, Schuurink E, et al. Identification of inguinofemoral lymph node metastases by methylation markers in vulvar cancer. *Gynecol Oncol.* 2012;125(2):352-7.
80. Rosenthal AN, Hopster D, Ryan A, Jacobs IJ. Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. *Br J Cancer.* 2003;88(2):251-6.
81. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. *NatMed.* 2011;17(3):330-9.



